LPCN · Lipocine Inc.

The resignation of Dr. Spyros Papapetropoulos represents a significant governance event for Lipocine Inc., given his role as Chairman, Lead Independent Director, and compensation committee member. The disclosure explicitly attributes his departure to differing views on the Company's strategic direction, suggesting potential friction in the boardroom regarding future corporate strategy. This level of detail regarding the reason for departure is notable for investors as it signals active strategic debates within the board. The swift appointment of R. Dana Ono to the Chairman and Lead Independent Director roles ensures continuity in leadership, though the transition occurred four days after the resignation became effective.